Human sera were examined by immunoblotting for antibodies against the polymerase (reverse transcriptase) believed to be encoded in the P open reading frame (ORF) of human hepatitis B virus (HBV). Sera from patients with self-limited and chronic hepatitis reacted specifically with fusion proteins containing different domains of the P ORF. The results indicate that this ORF is expressed, and that the corresponding proteins contain at least two immunogenic domains. In contrast to human immunodeficiency virus, induction of antibodies against reverse transcriptase appears to be less common for HBV, and may depend on long persistence of infection.
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SUMMARY Human sera were examined by immunoblotting for antibodies against the polymerase (reverse transcriptase) believed to be encoded in the P open reading frame (ORF) of human hepatitis B virus (HBV). Sera from patients with self-limited and chronic hepatitis reacted specifically with fusion proteins containing different domains of the P ORF. The results indicate that this ORF is expressed, and that the corresponding proteins contain at least two immunogenic domains. In contrast to human immunodeficiency virus, induction of antibodies against reverse transcriptase appears to be less common for HBV, and may depend on long persistence of infection.
DNA sequence analysis has allowed the mapping of the genes coding for the classical hepatitis B virus (HBV) markers and the identification of two open reading frames (ORFs) denoted X and P (for review, see Tiollais et al., 1985) . Nucleocapsid and envelope proteins of the predicted size have been identified. In contrast, gene products consistent in size with the X and P ORFs have not yet been detected. However, expression of the X protein in vivo is suggested by the presence of anti-X antibodies in sera from individuals with HBV infection (Elfassi et al., 1986; Kay et al., 1985; Meyers et al., 1986 , Moriarty et al., 1985 . The P ORF (polymerase) is believed to code for the viral reverse transcriptase (Patarca & Haseltine, 1984; Summers & Mason, 1982; Toh et al., 1983) . Fusion proteins believed to contain nucleocapsid protein sequences and NH2-terminal sequences of the polymerase protein have been found in HBVinfected liver and hepatocellular carcinoma tissues . In this study we screened human sera for antibodies recognizing the middle and COOH-terminal part of the HBV polymerase protein to provide evidence for expression of the complete putative HBV reverse transcriptase gene in vivo.
Different parts of HBV reading frames ( Fig. 1) were cloned in the expression vector pPlc24 and derivatives thereof and in vector pExl (Remaut et al., 1981 ; Stanley & Luzio, 1984; Strebel et al., 1986) . Correct cloning was proven by dideoxynucleotide sequencing of the vector-insert junction. All oligonucleotides (20 nucleotides long) were chemically synthesized, and hybridized to sequences approximately 30 nucleotides upstream of the linker regions of the MS2 polymerase (M) or fl-galactosidase (fl) expression vectors. Hybrid proteins containing M or fl sequences fused to the C gene, P ORF or X ORF sequences of HBV were obtained (Fig. 1 a) . After partial purification (Kfipper et al., 1982) followed by separation by gel electrophoresis (Fig. 1 b) these proteins were used for immunoblot analysis (Gershoni & Palade, 1983) . The migration behaviour of each fusion protein was in close agreement with the respective predicted size ( Fig Four different sets of human sera were first screened for HBV polymerase antibodies (anti-P) by immunoblot analysis with the MP2 protein: anti-HB core antigen-(anti-HBcAg) positive sera of 65 patients having undergone a self-limited hepatitis (set 1), sera of 23 acutely (set 2) and eight chronically (set 3) infected patients, and 67 sera devoid of any HBV markers (set 4). Three sera, one of set 1 (serum A) and two of set 3 (sera B and C) reacted with the MP2 protein and were analysed in more detail by immunoblotting (sera dilutions 1 : 200) with all HBV fusion proteins to demonstrate the specificity of the reaction and to locate the antigenic domain(s). HBV serological markers of these three sera are compared in Table 1 .
Serum A reacted only with two of the four HBV polymerase fusion proteins (MP1 and MP2) (Fig. 2a) . The reaction with both fusion proteins could be blocked by preincubating the serum with either fusion protein (Fig. 2b, c) but not with the X-specific fusion protein MX (Fig. 2d) . The observation that the reactivity of the long polymerase fusion protein MP1 could be completely blocked by MP2 which contains only a short P ORF-derived protein indicates that serum A reacts specifically with an antigenic domain located in the middle part of the P ORF. The negative reaction with fusion proteins MP3 and /~P3 which contain COOH-terminal polymerase sequences supports this conclusion.
Notably, in contrast to other sera, the HBc antibodies in serum A previously determined by an ELISA could not be detected by immunoblotting (Fig. 2, lanes 5) lower sensitivity of the immunoblot assay. Therefore, it is conceivable that low titres of anti-P antibodies might also escape detection in this assay. Serum A did not react with the X fusion protein, MX, (Fig. 2a to d , lanes 6) whereas another human serum previously shown to contain anti-X antibodies (data not shown) reacted strongly (Fig. 2e, lane 6 ). This result suggests that serum A does not contain substantial amounts of anti-X antibodies. A similar analysis of P antibodies was performed with serum B (Fig. 3 ). It reacted with the same or a similar P ORF domain as serum A (Fig. 3a, b, lanes 1 and 2) , and in addition with both fusion proteins containing COOH-terminal sequences of the polymerase protein (Fig. 3a,  lanes 3 and 4) . As expected for a specific reaction, preincubation of serum B with MP3 abolished the immune reaction with the filter-bound MP3 protein (Fig. 3b, lane 3) and, in addition, also that of the corresponding fusion protein/~P3 (Fig. 3b, lane 4) . Preincubation of serum B with the tiP3 fusion protein also gave similar results (data not shown). In contrast, preincubation with MP3 did not affect antibody binding to the MP2 protein, and reduced only partially the reaction to MP1 (Fig. 3b , lanes 2 and 1) suggesting that serum B like serum A reacts with an antigenic site that is located in the middle part of P ORF. Taken together, these data revealed a second antigenic domain at the COOH terminus of the P ORF recognized by serum B. This conclusion is confirmed by the prevention of antibody binding to all polymerase proteins by preincubation of the serum with the MP 1 protein (Fig. 3 c, lanes 1 to 4) . As shown previously for serum A, serum B also lacked detectable X antibodies (data not shown). In serum C, X and P antibodies were found (Fig. 4) . All P ORF-derived fusion proteins reacted with serum C. Thus, this serum appears to contain P antibodies to both previously defined antigenic domains of the polymerase protein (Fig. 4a, lanes 1 to 4) . This was confirmed by preincubation of the serum with the MP1 protein which virtually abolished the signals with all P ORF-derived proteins (Fig. 4b, lanes 1 to 4) . In contrast, the strong reaction of the serum with the X protein (Fig. 4a, lane 5) was not prevented in the same experiment (Fig. 4b, lane 5) demonstrating the specificity of competition with the MP1 protein.
In this study, antibodies binding to two antigenic domains of the polymerase protein were recognized in three out of 96 sera with HBV markers but in none of 67 control sera (data not shown). Since the sensitivity of the immunoblot assay is probably low, the frequency of anti-P antibodies may be higher than reflected by these results. Additionally, infrequent detection of an immune response to the polymerase protein may be due to low expression, weak immunogenicity and rare exposure of the polymerase proteins to immunocompetent cells. The finding of P antibodies in sera of HBV-infected patients is the first evidence for expression of COOH-terminal sequences of the P ORF during HBV infection. The identification of antigenic domains in the middle and COOH-terminal part of the polymerase protein, and the expression of NH2-terminal sequences of the polymerase protein in infected liver tissue suggest that most or all of the P ORF sequences are expressed in vivo.
High and frequent immunogenicity of reverse transcriptase has been reported for human immunodeficiency virus (Di Marzo Veronese et al., 1986 ). Our studies suggest that HBV
